These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7620213)

  • 1. Proceedings of the International Conference on Bioreductive Drug Activation. Lake Tahoe, California, August 16-19, 1994.
    Oncol Res; 1994; 6(10-11):459-559. PubMed ID: 7620213
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent developments in the design of bioreductive drugs.
    Denny WA; Wilson WR; Hay MP
    Br J Cancer Suppl; 1996 Jul; 27():S32-8. PubMed ID: 8763842
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioreductive prodrugs for cancer therapy.
    Seddon B; Kelland LR; Workman P
    Methods Mol Med; 2004; 90():515-42. PubMed ID: 14657582
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
    Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
    Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
    Workman P
    Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 8th International Conference on Chemical Modifiers of Cancer Treatment. Part 1. Proceedings. Kyoto, Japan, June 16-19, 1993.
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):229-412. PubMed ID: 7910815
    [No Abstract]   [Full Text] [Related]  

  • 8. Electrodrugs: an electrochemical prodrug activation strategy.
    Norman DJ; González-Fernández E; Clavadetscher J; Tucker L; Staderini M; Mount AR; Murray AF; Bradley M
    Chem Commun (Camb); 2018 Aug; 54(66):9242-9245. PubMed ID: 30066701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitro reduction as an electronic switch for bioreductive drug activation.
    Siim BG; Denny WA; Wilson WR
    Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.
    O'Connor LJ; Cazares-Körner C; Saha J; Evans CN; Stratford MR; Hammond EM; Conway SJ
    Nat Protoc; 2016 Apr; 11(4):781-94. PubMed ID: 27010756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
    Lee AE; Wilson WR
    Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings of the International Conference on Bone Morphogenetic Proteins. June 7-11, 2000. Lake Tahoe, California, USA.
    J Bone Joint Surg Am; 2001; 83-A Suppl 1(Pt 1):S1-78. PubMed ID: 11305283
    [No Abstract]   [Full Text] [Related]  

  • 14. International Conference on Herpetic Eye Diseases. North Lake Tahoe, California, USA, September 6-8, 1986. Proceedings.
    Curr Eye Res; 1987 Jan; 6(1):1-286. PubMed ID: 3829697
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzymology of bioreductive drug activation.
    Ross D; Beall HD; Siegel D; Traver RD; Gustafson DL
    Br J Cancer Suppl; 1996 Jul; 27():S1-8. PubMed ID: 8763836
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioreductive agents: a clinical update.
    Boyer MJ
    Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.
    Nemirovski A; Vinograd I; Takrouri K; Mijovilovich A; Rompel A; Gibson D
    Chem Commun (Camb); 2010 Mar; 46(11):1842-4. PubMed ID: 20198227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
    Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
    Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs.
    Cytarska J; Misiura K; Filip-Psurska B; Wietrzyk J
    Acta Pol Pharm; 2013; 70(3):481-7. PubMed ID: 23757939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.